We cut 2026E adjusted EBITA by 9% and 2027E-28E by 4-6% ahead of the Q1 report, due to FX and an ong...
While we believe there are growth levers in the existing business, we think further license deals ar...
VBG Group redovisar ett stabilt Q4 med omsättning på 1 312 MSEK (+2,8%), men påverkas negativt av sv...
Magle has announced a rights issue aimed at strengthening its balance sheet, improving financial fle...
Redeye comments on Fractal's press release confirming the termination of IEEPA tariffs and the exemp...
Redeye comments on Smart Eye's SEK40m agreement with a European police authority for AI-based drug i...
We expect PFPM/share growth of 17% y/y in Q1, driven by higher NOI, lower financial expenses, and bu...
Redeye updates on Genovis following a new announcement.
Yesterday's rights issue announcement aligned closely to the scenario we discussed in our previous r...
On Monday, q.beyond announced and presented its 2028 strategy, including financial targets (2028) an...
Redeye comments on EG7’s announcement of EverQuest Legends, which is a new game based on the origina...
* I väntan på EFSA-beslutet fortsätter etableringen av aXiphen i Brasilien * Den positiva trenden fö...
Cereno Scientific’s FY25 results mark a strategically productive period, with multiple value inflect...
We look for mid-single growth in CDON’s group GMV in Q1.
Mendus has announced a new clinical collaboration with the Olivia Newton-John Cancer Research Instit...
This morning, OXE Marine announced a raise of SEK60m, which includes a directed share issue and conv...
* Produktlanseringar och skalbarhet ger lönsam tillväxt * Starkt 2025 ger medvind framöver * Vi inle...
Redeye comments on Alligator Bioscience’s outcome of its TO14 warrant exercise, which adds approxima...
Q1 2026E is set to show improving profitability in Technology & Distribution, while Energy & Environ...
Redeye has opened an Analyst Q&A following the recent share price movement and unusually high tradin...
